Journal article icon

Journal article

Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation.

Abstract:

BACKGROUND: Rimonabant is a selective type 1 cannabinoid (CB1) receptor antagonist. It may assist with smoking cessation by restoring the balance of the endocannabinoid system, which can be disrupted by prolonged use of nicotine. Rimonabant also seeks to address many smokers' reluctance to persist with a quit attempt because of concerns about weight gain. OBJECTIVES: To determine whether selective CB1 receptor antagonists increase the numbers of people stopping smoking. To assess their effect...

Expand abstract
Publication status:
Published

Actions


Access Document


Journal:
Cochrane database of systematic reviews More from this journal
Issue:
4
Pages:
CD005353
Publication date:
2007-01-01
DOI:
EISSN:
1469-493X
ISSN:
1469-493X
Language:
English
Keywords:
Pubs id:
pubs:214363
UUID:
uuid:c8561272-b1cc-455b-baff-f062dad1815d
Local pid:
pubs:214363
Source identifiers:
214363
Deposit date:
2012-12-19

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP